ALTH Allos Therapeutics, Inc. (MM)

Reminder - Webcast Alert: Allos Therapeutics, Inc. Announces Third Quarter 2003 Financial Results Conference Call on the Web WESTMINSTER, Colo., Nov. 6 /PRNewswire-FirstCall/ -- Allos Therapeutics, Inc. announces the following Webcast: What: Allos Therapeutics Third Quarter 2003 Financial Results Conference Call Webcast When: November 6, 2003 @ 11:00 AM EST Where: http://www.firstcallevents.com/service/ajwz392805477gf12.html How: Live over the Internet -- Simply log on to the web at the address above or Live Call: Domestic: 1-800-915-4836; International: 1-973-317-5319; no passcode required. Replay: Domestic: 1-800-428-6051; International: 1-973-709-2089; Passcode: 311459. The replay will be available for five business days following the call. Contact: Laurel Beltran, 303-426-6262, Allos Therapeutics, Inc. is a biopharmaceutical Company focused on developing and commercializing innovative drugs for improving cancer treatments. The Company's lead clinical candidate, RSR13 (efaproxiral), is a synthetic small molecule that has the potential to sensitize hypoxic (oxygen deprived) tumor tissues and enhance the efficacy of standard radiation therapy. In addition, Allos is developing PDX, a novel small molecule cytotoxic injectable anti-folate (DHFR inhibitor) being developed for non-small cell lung cancer, mesothelioma and non-Hodgkin's lymphoma. For more information, please visit the Company's web site at: http://www.allos.com/ . (Minimum Requirements to listen to broadcast: The Windows Media Player software, downloadable free from http://www.microsoft.com/windows/windowsmedia/EN/default.asp and at least a 28.8Kbps connection to the Internet. If you experience problems listening to the broadcast, send an email to ). PRNewswire-FirstCall -- Nov. 6 DATASOURCE: Allos Therapeutics, Inc. Web site: http://www.allos.com/

Copyright